Stock Option Award to CFO of Pasithea Therapeutics Corp.

On October 24, 2025, Daniel H. Schneiderman, the Chief Financial Officer of Pasithea Therapeutics Corp., was awarded 317,266 stock options under the company's 2023 Stock Incentive Plan. The options, which grant the right to buy common stock at $0.715 per share, will vest over three years, with 33% vesting after one year and the remainder in equal quarterly installments. Full vesting occurs upon a Change in Control. The options expire on October 23, 2035, and can be exercised for up to three years following termination of service, except in cases of termination for Cause.